tiprankstipranks
Trending News
More News >

Rhythm Biosciences Announces New Cancer Detection Products

Story Highlights
Rhythm Biosciences Announces New Cancer Detection Products

Don’t Miss TipRanks’ Half-Year Sale

Rhythm Biosciences Ltd. ( (AU:RHY) ) has issued an update.

Rhythm Biosciences Ltd. has announced the commercial availability of its geneType product and anticipates the launch of ColoSTAT in the second half of 2025. These products, protected by patents, are designed for easy adoption in routine laboratories and represent a significant advancement in cancer risk assessment and detection, potentially impacting the company’s market positioning and offering valuable solutions to stakeholders.

More about Rhythm Biosciences Ltd.

Rhythm Biosciences Ltd. operates in the healthcare industry, focusing on cancer risk evaluation and early detection. The company offers innovative proteomic and genomic technologies, targeting large underserved global markets, and is supported by both public and private healthcare systems.

Average Trading Volume: 230,838

Technical Sentiment Signal: Sell

Current Market Cap: A$16.84M

Learn more about RHY stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1